Skip to main content
SpringerLink
Log in
Book cover

Tumors of the Chest pp 189–197Cite as

Prognostic Factors for Small-Cell Lung Cancer

  • Chapter

  • 821 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4(2):31.

    PubMed  CAS  Google Scholar 

  2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111(6):1710.

    PubMed  CAS  Google Scholar 

  3. Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107.

    Article  PubMed  CAS  Google Scholar 

  4. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340(4):265.

    Article  PubMed  CAS  Google Scholar 

  5. Stahel R, Aisner J, Ginsberg R, et al. Staging and prognostic factors in small cell lung cancer. Lung Cancer 1989; 5:119.

    Article  Google Scholar 

  6. Shepherd FA, Ginsberg RJ, Haddad R, et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993; 11:1592.

    PubMed  CAS  Google Scholar 

  7. Shields TW, Higgins GA Jr, Matthews MJ, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982; 84(4):481.

    PubMed  CAS  Google Scholar 

  8. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999; 17(9):2681.

    PubMed  CAS  Google Scholar 

  9. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989; 7(3):344.

    PubMed  CAS  Google Scholar 

  10. Urban T, Chastang C, Vaylet F, et al. Prognostic significance of supraclavicular lymph nodes in small cell lung cancer: a study from four consecutive clinical trials, including 1,370 patients. “Petites Cellules” Group. Chest 1998; 114(6):1538.

    PubMed  CAS  Google Scholar 

  11. Livingston RB, McCracken JD, Trauth CJ, Chen T. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. Chest 1982; 81(2):208.

    PubMed  CAS  Google Scholar 

  12. Dearing MP, Steinberg SM, Phelps R, Anderson MJ, Mulshine JL, Ihde DC, Johnson BE. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 1990; 8(6):1042.

    PubMed  CAS  Google Scholar 

  13. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome of small-cell lung cancer: an analysis of the 2, 580-patient Southwest Oncology Group database. J Clin Oncol 1990; 8(9):1563.

    PubMed  CAS  Google Scholar 

  14. Sagman U, Maki E, Evans WK, et al. Small-cell carcinoma of the lung: derivation of prognostic staging system. J Clin Oncol 1991; 9(9):1639.

    PubMed  CAS  Google Scholar 

  15. Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. Norwegian Lung Cancer Study Group. The value of prognostic factors in small cell lung cancer: results from a randomized multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39(3):303.

    Article  PubMed  Google Scholar 

  16. Tas F, Aydiner A, Topuz E, Camlica H, Saip P, Eralp Y. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol 1999; 38(8):1011.

    Article  PubMed  CAS  Google Scholar 

  17. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11(2):336.

    PubMed  CAS  Google Scholar 

  18. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316(15):912.

    Article  PubMed  CAS  Google Scholar 

  19. Vincent MD, Ashley SE, Smith IE. Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol 1987; 23(11):1589.

    Article  PubMed  CAS  Google Scholar 

  20. Wurschmidt F, Bunemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 1995; 33(1):77.

    Article  PubMed  CAS  Google Scholar 

  21. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985; 45(6):2878.

    PubMed  CAS  Google Scholar 

  22. Harper PG, Souhami RL, Spiro SG, Geddes DM, Guimaraes M, Fearon F, Smyth JF. Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy. Cancer Treat Rep 1982; 66(3):463.

    PubMed  CAS  Google Scholar 

  23. Osterlind K, Hansen HH, Dombernowsky P, Hansen M, Andersen PK. Determinants of complete remission induction and maintenance in chemotherapy with or without irradiation of small cell lung cancer. Cancer Res 1987; 47(10):2733.

    PubMed  CAS  Google Scholar 

  24. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing’s syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 1992; 10(l):21.

    PubMed  CAS  Google Scholar 

  25. Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PE, Vassilopoulou-Sellin R. Paraneoplastic Cushing’s syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 1992; 69(1):66.

    Article  PubMed  CAS  Google Scholar 

  26. Gronowitz JS, Bergstrom R, Nou E, et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 1990; 66:722.

    Article  PubMed  CAS  Google Scholar 

  27. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on the Cancer Research, [published erratum in Br J Cancer 62:550] Br J Cancer 1990; 61:597.

    PubMed  CAS  Google Scholar 

  28. Siu LL, Shepard FA, Murray N, et al. Influence of age on treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996; 14:821.

    PubMed  CAS  Google Scholar 

  29. Osterlind K, Anderson PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46(8):4189.

    PubMed  CAS  Google Scholar 

  30. Christodolou C, Pavlidis N, Samantas E, et al. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. Anticancer Res 2002; 22(6B):3749.

    PubMed  CAS  Google Scholar 

  31. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987; 39(2):146.

    PubMed  CAS  Google Scholar 

  32. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327(23):1618.

    Article  PubMed  CAS  Google Scholar 

  33. Wolf M, Holle R, Hans K, et al. Analysis of prognostic factors in 766 patients with small cell lung cancer: the role of sex as a predictor for survival. Br J Cancer 1991; 63:986.

    PubMed  CAS  Google Scholar 

  34. Tas F, Aydiner A, Demir C, Topuz E (2001). Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol 2001; 4(4):376.

    Article  Google Scholar 

  35. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 1986; 2(5):771.

    Google Scholar 

  36. Carney DN, Marangos PJ, Ihde DC, Bvinn PA Jr, Cohen MH, Minna JD, Gazdar AF. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982; 1:583.

    Article  PubMed  CAS  Google Scholar 

  37. Jorgensen LGM, Osterlind K, Genolle J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariate analysis on data from nine centres. Br J Cancer 1996; 74:463.

    PubMed  CAS  Google Scholar 

  38. Harding M, McAllister J, Hulks G, et al. Neuron specific enolase (NSE) in small cell lung cancer: a tumour marker for prognostic significance? Br J Cancer 1990; 61:605.

    PubMed  CAS  Google Scholar 

  39. Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993; 67:760.

    PubMed  CAS  Google Scholar 

  40. Gomm SA, Keevil BG, Thatcher N, Hastleton PS, Swindell RS. The value of tumour markers in lung cancer. Br J Cancer 1988; 58:797.

    PubMed  CAS  Google Scholar 

  41. Van Der Gaast A, Van Putten WLJ, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TA. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 1991; 64:369.

    PubMed  Google Scholar 

  42. Ebert W, Muley T, Trainer C, Dienemann H, Drings P. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Anticancer Res 2002; 22(2B):1083.

    PubMed  CAS  Google Scholar 

  43. Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 1998; 82(6):1049.

    Article  PubMed  CAS  Google Scholar 

  44. Buccheri G, Ferrigno D. Serum biomarkers or non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase. Lung Cancer 2000; 30(l):37.

    Article  PubMed  CAS  Google Scholar 

  45. Niho S, Nishiwaki Y, Goto K, et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000; 27(3):159.

    Article  PubMed  CAS  Google Scholar 

  46. Bandoh S, Fujita J, Ueda Y, et al. Expression of carcinoembryonic antigen in peripheral-or central-located small cell lung cancer: its clinical significance. Jpn J Clin Oncol 2001; 31(7):305.

    Article  PubMed  CAS  Google Scholar 

  47. Schneider J, Philipp M, Salewski L, Velcovsky HG. Progastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Clin Lab 2003; 49(1–2):35.

    PubMed  CAS  Google Scholar 

  48. Oremek GM, Sapoutzis N. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer. Anticancer Res 2003; 23(2A):895.

    PubMed  CAS  Google Scholar 

  49. Okusaka T, Eguchi K, Kasai T, et al. Serum levels of progastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997; 3(1):123.

    PubMed  CAS  Google Scholar 

  50. Lamy P, Grenier J, Kramer A, Pujol JL. Progastrin-releas ing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000; 29(3):197.

    Article  PubMed  CAS  Google Scholar 

  51. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003; 39(2):131.

    Article  PubMed  Google Scholar 

  52. Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001; 32(1):61.

    Article  PubMed  CAS  Google Scholar 

  53. Sunaga N, Tsuchiya S, Minato K, et al. Serum pro-gastrinreleasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999; 57(2):143.

    Article  PubMed  CAS  Google Scholar 

  54. Naeem M, Dahiya M, Clark JI, Creech SD, Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 2002; 33(12):1182.

    Article  PubMed  CAS  Google Scholar 

  55. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003; 9(1):188.

    PubMed  CAS  Google Scholar 

  56. Rohr UP, Rehfeld N, Pflugfelder L, et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004; 111(2):259.

    Article  PubMed  CAS  Google Scholar 

  57. Potti A, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003; 14(6):894.

    Article  PubMed  CAS  Google Scholar 

  58. Boldrini L, Ursino S, Gisfredi S, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res 2004; 10(12 Pt l):4101.

    Article  PubMed  CAS  Google Scholar 

  59. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Can cer Res 2003; 9(16 Pt l):5880.

    CAS  Google Scholar 

  60. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79(2):144.

    Article  PubMed  CAS  Google Scholar 

  61. Dowell JE, Amirkhan RH, Lai WS, Frawley WH, Minna JD. Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2. Anticancer Res 2004; 24(4):2367.

    PubMed  CAS  Google Scholar 

  62. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999; 17(6):1802.

    PubMed  CAS  Google Scholar 

  63. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22):4434.

    Article  PubMed  CAS  Google Scholar 

  64. Rohr UP, Rehfeld N, Geddert H, et al. Prognostic rele vance of fragile histidine triad protein expression in pa tients with small cell lung cancer. Clin Cancer Res 2005; 11(l):180.

    PubMed  CAS  Google Scholar 

  65. Zereu M, Vinholes JJ, Zettler CG. p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin Lung Cancer 2003; 4(5):298.

    Article  PubMed  CAS  Google Scholar 

  66. Oshita F, Kameda Y, Hamanaka N, Saito H, Yamada K, Noda K, Mitsuda A. High expression of integrin beta 1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol 2004; 27(3):215.

    Article  PubMed  CAS  Google Scholar 

  67. Rosenfeld MR, Malats N, Schramm L, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997; 89(5):381.

    Article  PubMed  CAS  Google Scholar 

  68. Jassem E, Bigda J, Dziadziuszko R, et al. Serum p53 anti bodies in small cell lung cancer: the lack of prognostic relevance. Lung Cancer 2001; 31(1):17.

    Article  PubMed  CAS  Google Scholar 

  69. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15(8):2866.

    PubMed  CAS  Google Scholar 

  70. Monstad SE, Drivsholm L, Storstein A, et al. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 2004; 22(5):795.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA

    Chad M. DeYoung

  2. Medical Thoracic Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA

    Martin J. Edelman

Authors
  1. Chad M. DeYoung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin J. Edelman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos MD, PhD

  2. Royal Marsden NHS Trust Hospitals, London, UK

    Christopher M. Nutting MB BA, MD, FRCR

  3. Evangelismos General Hospital, Athens Medical School, Athens, Greece

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

  4. Faculty of Medicine, McGill University, Montreal, Canada

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

DeYoung, C.M., Edelman, M.J. (2006). Prognostic Factors for Small-Cell Lung Cancer. In: Syrigos, K.N., Nutting, C.M., Roussos, C. (eds) Tumors of the Chest. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-31040-1_15

Download citation

  • DOI: https://doi.org/10.1007/3-540-31040-1_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31039-6

  • Online ISBN: 978-3-540-31040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation